Study of Colchicine to Treat and Prevent Recurrent Pericarditis After Failure of Conventional Treatment. (CORP 2)
Pericarditis, Recurrence
About this trial
This is an interventional treatment trial for Pericarditis focused on measuring Pericarditis, Recurrence, Therapeutics, Prevention, Colchicine
Eligibility Criteria
Inclusion Criteria: Patients with the second and subsequent attack of recurrent pericarditis, Age≥ 18 years, Informed consent. Exclusion Criteria: Suspected neoplastic, tuberculous, or purulent etiology, Known severe liver disease and/or elevated transaminases >1.5 times the upper limit of normality, serum creatinine>2.5 mg/dl, Serum CK over the upper limit of normality or Known myopathy, Known gastrointestinal or blood disease, Pregnant or lactating women or women not protected by a contraception method, Known hypersensibility to colchicine, Treatment with colchicine at the enrolment.
Sites / Locations
- Azienda Ospedaliera Papa Giovanni XXIII
- Ospedale Regionale
- Ospedale di Rivoli
- Cardiology Department. Maria Vittoria Hospital ASL3 Torino (Coordinating Center)
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Colchicine
Placebo
Colchicine 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
Placebo 0.5mg BID (>70Kg) or 0.5 once daily for 6 months